|Lonza Invests to Develop Exosomes for Next-Generation Life-Science Applications|
Exosomes technology will leverage Lonza’s portfolio of drug discovery products, as well as its development and manufacturing expertise in mammalian cell culture
Lonza, a global leader in the field of biopharmaceutical development and manufacturing, announced today the acquisition of HansaBioMed Life Sciences OÜ (HBM-LS), based in Tallinn, Estonia, a start-up company dedicated to the research and development, manufacturing, and distribution of products for the exosomes research market.
“Exosomes represent a dynamically growing segment in life sciences with opportunities in research, diagnostics and therapeutic applications,” said Dr. Uwe Gottschalk, Chief Technology Officer for Lonza Pharma&Biotech.
“Exosomes may play an important role in the promising field of liquid biopsies and could become the next generation of cell-free therapies in regenerative medicine," he added.
Dr. Antonio Chiesi, managing director of HBM-LS and Chief Executive Officer of Exosomics, said, “The next step in the evolution of exosome technology into diagnostics and therapeutics is the development of larger-scale procedures for isolation, purification and characterization of specific types of exosomes. Cell-culture capabilities are a critical component of this next step. Lonza’s infrastructure and leadership rolein bio-manufacturing, combined with our exosome knowledge, will accelerate the availability of these breakthrough modalities.”
As a new part of Lonza, HBM-LSwill continue its product portfolio expansion of research products and support the development of cGMP-compliant exosome manufacturing processes.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
About HansaBioMed Life Sciences
HansaBioMed Life Sciences OÜ located in Tallinn, Estonia, is the oldest company entirely dedicated to research and development of products and specialized services in the field of exosome sciences. Our mission is to develop and commercialize proprietary platforms, kits, reagents and equipment for exosomes research in the Life Science market and to support scientists and industries to best develop their MV based projects.HansaBioMedLife Sciences has 6 permanent employees.